+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of corticoid-induced osteoporosis by 3-monthly intravenous ibandronate injections

Treatment of corticoid-induced osteoporosis by 3-monthly intravenous ibandronate injections

Journal of Bone & Mineral Research 15(Suppl 1): S150, September

(PDF emailed within 1 workday: $29.90)

Accession: 035981505

Download citation: RISBibTeXText

Related references

Tri-monthly intravenous injections of ibandronate for treatment of postmenopausal osteoporosis. Journal of Bone & Mineral Research 16(Suppl 1): S406, September, 2001

Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. American Journal of Medicine 103(4): 298-307, 1997

Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis. Osteoporosis International 26(11): 2685-2693, 2016

Ibandronate: once-monthly and intravenous dosing options for osteoporosis treatment. Women's Health 2(3): 341-349, 2006

Increase by 10% of spine bone mineral density and effect on bone markers of three monthly intravenous injections of ibandronate in osteoporosis in men with Klinefelters syndrome. Journal of Bone & Mineral Research 15(Suppl 1): S226, September, 2000

Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study. Journal of Bone and Mineral Metabolism (): -, 2015

Three-monthly 2mg intravenous ibandronate injections restore bone turnover to premenopausal levels. Journal of Bone & Mineral Research 17(Suppl 1): S472, September, 2002

Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis and Rheumatism 54(6): 1838-1846, 2006

Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporosis International 14(10): 801-807, 2003

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Clinical Therapeutics 31(4): 751-761, 2009

Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34(5): 890-899, 2004

Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis. Therapeutics and Clinical Risk Management 2(1): 3-18, 2008

Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. Journal of Rheumatology 35(3): 488-497, 2008

Increased bone mineral density with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the MOVER study. Calcified Tissue International 95(6): 557-563, 2015

Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. Current Medical Research and Opinion 25(12): 2951-2960, 2010